Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Another Positive Phase III For Lilly's, Incyte's Baricitinib

This article was originally published in Scrip

Executive Summary

Eli Lilly & Co. and Incyte Corp. reported on Sept. 29 that baricitinib bested the first-line rheumatoid arthritis (RA) standard of care methotrexate in a late-stage clinical trial, so now the partners must complete just one more Phase III trial before seeking regulatory approvals for the JAK inhibitor.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register